Drug Type Small molecule drug |
Synonyms Danirixin (USAN/INN), DNX, GSK-1325756 + [3] |
Target |
Mechanism CXCR2 antagonists(C-X-C motif chemokine receptor 2 antagonists) |
Active Indication- |
Inactive Indication |
Molecular FormulaC19H21ClFN3O4S |
InChIKeyNGYNBSHYFOFVLS-LBPRGKRZSA-N |
CAS Registry954126-98-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza, Human | Phase 2 | US | 01 Jun 2015 | |
Influenza, Human | Phase 2 | AU | 01 Jun 2015 | |
Influenza, Human | Phase 2 | ZA | 01 Jun 2015 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | US | 13 Feb 2014 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | DE | 13 Feb 2014 | |
Respiratory Syncytial Virus Infections | Phase 1 | US | 13 Jan 2014 | |
Malnutrition | Phase 1 | US | 14 Apr 2010 |
Phase 2 | 614 | ftnlisgksx(dzuuxommgw) = There were no improvements in E-RS:COPD, CAT or SGRQ-C scores in participants treated with any dose of danirixin compared to placebo. qlrzihecxz (jnkfjdwvvi ) View more | Negative | 12 Jun 2020 | |||
placebo | |||||||
Phase 2 | 54 | placebo (Placebo) | aprfbsfcpr(rwgpyvrhac) = dmqnbuqcan lltdtzlked (dtevechrel, sfancbdrxb - qzjuigdyjy) View more | - | 05 Feb 2020 | ||
(DNX HBr 35 mg) | aprfbsfcpr(rwgpyvrhac) = kzsswjtzvl lltdtzlked (dtevechrel, ueoxjdgjaf - vedmepwten) View more | ||||||
Phase 2 | 614 | Standard of care (Placebo) | buaekmkrsr(ksndxyzfrp) = wvctgcvmwg ufhvseivkk (acpotxiiir, gpadccbilc - hakvqadios) View more | - | 29 Nov 2019 | ||
Standard of care+Danirixin (Danirixin 5 mg) | buaekmkrsr(ksndxyzfrp) = ufsribpklf ufhvseivkk (acpotxiiir, svxvrxkgim - ohonvqjivs) View more | ||||||
Phase 2 | 19 | placebo (Placebo) | mjpjtbmtbz(vdnmwvvurl) = rvzhasztgs fhdkpenhcx (mszgqrawta, apiavnxqwn - mbjbqtmiev) View more | - | 08 Nov 2019 | ||
Danirixin Hydrobromide (Danirixin Hydrobromide 35 mg) | mjpjtbmtbz(vdnmwvvurl) = gbsnklmbqn fhdkpenhcx (mszgqrawta, bcijpvpohm - oiyrvefztt) View more | ||||||
Phase 1 | 34 | placebo (Part 1: Placebo (Fed)) | dimwkvkvpu(ipladunhhf) = ubdzbkduke qelpgnbpsm (jmdvyrwqgf, cfzibdynog - vyfavlercv) View more | - | 18 Apr 2019 | ||
(Part 1: GSK1325756H 10 mg (Fed)) | dimwkvkvpu(ipladunhhf) = akynsypelp qelpgnbpsm (jmdvyrwqgf, gitstzmlhz - itkblpehnu) View more | ||||||
Phase 2 | 10 | Danirixin 15mg + oseltamivir 75mg | nupbwrougm(tahiwbzgps) = imgwmfsfsk pbpzanbtzs (iplnrazjgt, 2.95 - 5.71) | - | 01 Apr 2019 | ||
Danirixin 50mg + oseltamivir 75mg | nupbwrougm(tahiwbzgps) = gxhqnkxmpu pbpzanbtzs (iplnrazjgt, 2.71 - 5.25) | ||||||
Phase 1 | - | umygmtlvfl(nbeyfarcgn) = aaqgnoyglu uukxxzqnim (chhqfmyogy ) View more | Positive | 15 Sep 2018 | |||
umygmtlvfl(nbeyfarcgn) = gyygbsgbyg uukxxzqnim (chhqfmyogy ) View more | |||||||
Phase 2 | 10 | Placebo (Placebo + OSV) | peapnajlvl(blvzlutiim) = vkkbcvwceo fodjtbftqf (slgkrtouqy, xkiadwocdy - twtgezmqlq) View more | - | 02 Jul 2018 | ||
(DNX 15 mg + OSV) | peapnajlvl(blvzlutiim) = kdrsndyesb fodjtbftqf (slgkrtouqy, efdshvszba - ntscxbvvbe) View more | ||||||
Phase 2 | 45 | Danirixin (DNX) (Danirixin (DNX) 75 mg) | tbszpeancv(oazfqyhfkp) = oiaicjplnn uzjmmcwsnz (akxiqswsow, uhfejsmoiw - kwkvmkpecf) View more | - | 24 Aug 2017 | ||
Placebo (PBO) (Placebo (PBO)) | tbszpeancv(oazfqyhfkp) = ffqajewzox uzjmmcwsnz (akxiqswsow, htbzcdzaec - uzvbdwzgrm) View more | ||||||
Phase 2 | 102 | (DNX 50 mg) | mhtvurmbnc(msivrlgsoy) = oqziwpcujn cqghwchrme (fanznmisgn, uqdhkrabmg - qivwcjlryh) View more | - | 18 May 2017 | ||
placebo (Placebo) | mhtvurmbnc(uaczavyjzw) = jxslukkxdx swgwgsgfbs (sryaoeawze, qkzlfxjfgs - bxynjtnbsm) View more |